Dr Fiona Day
(BSc(Hons), MBBS, FRACP, PhD)
|Research Areas||Genetics, Therapy and Treatment|
|Research Topics||Head and Neck Cancer, Gastrointestinal Cancer|
|Research Types||Clinical Trials, Laboratory Research, Dissemination / Implementation|
Dr Fiona Day has been conducting clinical and translational research in the Department of Medical Oncology at the CMN since 2012. Her main interest is in the treatment of gastrointestinal cancers such as colorectal cancer. Dr Day’s previous PhD research looked at identifying different subtypes of colorectal cancer with the goal of treating each type more effectively. Her other research interests include the conduct of clinical trials of new therapies, cost-effectiveness in health care and the implementation of research findings into the clinic.
Publications / achievements
1. Day F, Kumar M, Fenton L, Gedye C. Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy. J Immunother, Epub 28 Sep 2016.
2. Segelov E, Waring P, Desai J, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F et al. ICECREAM: randomized phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PIK3CA wild type, or G13D mutated tumours. BMC Cancer 16: 339, 2016.
3. Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong H-L, Farragher I, Jones I, Day FL et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncologica 54: 487-92, 2015 12 citations
4. Day FL, Muranyi A, Singh S, Shanmugan K, Williams D, Byrne D, Pham K et al . A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Targeted Oncology 10: 99-109, 2015 11 citations
5. Day FL, Jorissen RN, Lipton L et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clinical Cancer Research 19: 3285-96, 2013 50 citations
6. Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Research 73: 725-35, 2013 85 citations
7. Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/-catenin signaling thresholds for tumourigenesis. Oncogene 32: 4675-82, 2013 27 citations
8. Day FL, Karnon K, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. Journal of Clinical Oncology 29:3270-7, 2011 37 citations
9. Day FL, Link E, Ngan S, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. British Journal of Cancer 105: 498-504, 2011 27 citations
10. Day FL, Bull J, Lombard J, Stewart J. Changes in medical oncology admissions for the management of breast cancer complications: An Australian institution’s experience. Asia-Pacific Journal of Clinical Oncology 7:146-53, 2011 4 citations
11. Day F, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: A nationwide survey of medical oncologists. Journal of Oncology Practice 7: 141-7, 2011 36 citations
12. Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Brit Journal of Cancer 104: 265-71, 2011 12 citations
13. Day FL, Desai J, Corless CL, Heinrich MC, Zalcberg J. Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. Medical Oncology 28 Suppl 1: S162-4, 2011 11 citations
14. Day FL, Rafty LA, Chesterman CN, Khachigian LM. ATII-inducible PDGF A-chain gene expression is p42/44 ERK- and Egr-1-dependent and mediated via the ATII type I but not type 2 receptor. Journal of Biological Chemistry 274: 726-33, 1999 61 citations
15. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. American Journal of Pathology 154: 937-44, 1999 129 citations
Awards and Prizes
Medical Oncology Group of Australia (MOGA) Best Consultant Abstract and Poster Award 2011
MOGA Annual Scientific Meeting, Adelaide, August 2011
American Society of Clinical Oncology (ASCO) Merit Award, Chicago, USA, June 2011
To complete research towards Doctorate of Medical Science (DMedSc) 2010-12, awarded:
National Health and Medical Research Council Research Scholarship (3 yrs)
Cancer Council Victoria Postgraduate Cancer Research Scholarship (2 yrs) - acceptedFaculty of Medicine, Dentistry and Health Sciences, University of Melbourne Postgraduate Research Scholarship
Pfizer Australia Cancer Research Grant (~$50,000) for 2011 - accepted
GlaxoSmithKline Australia Trainee Travel Award to the Medical Oncology Group of Australia 30th Anniversary Annual Scientific Meeting, Canberra August 2009
GlaxoSmithKline Australia Trainee Travel Award to the Australia and New Zealand Medical Oncology Joint Annual Scientific Meeting, Christchurch NZ August 2008
Awarded “Intern of the Year” in Illawarra Area Health Service 2003 (as per popular vote)
Dun Surgery Prize, University of Sydney 2002
RANZCP Faculty of Psychiatry of Old Age Student Essay Prize (Equal 2nd Place) 2002
Harold Alfred Waldon Memorial Prize, School of Infectious Diseases, University of Sydney 2001
Getting to know you
When did you start doing research?
1997, my Bachelor of Science Honours project was a 12 month project looking at the therapeutic transfer of genetic material into blood cells.
What research projects are you currently working on?
Clinical research projects in colorectal cancer looking at patterns of care and the benefit of aspirin treatment.
What research achievement are you most proud of?
Research awards chosen by peers, such as an American Society of Clinical Oncology Merit Award.
What inspires you?
The ability to incrementally, but continually, improve the health care that we can offer those affected by illness.
What did you do before coming to work at Calvary Mater Newcastle?
I was busy completing a laboratory PhD at the Ludwig Institute in Parkville, Melbourne.
What has helped you the most in your research at Calvary Mater Newcastle?
The collegial atmosphere – it encourages and facilitates many types of achievement.
Who are your main collaborators at Calvary Mater Newcastle?
Fellow oncologists working in radiation and medical oncology.
What did you do before you became a researcher?
I have been involved in research since leaving high school.
What made you decide to do research?
I have a love of science and research applies it to community benefit.
What was your first / worst / best / strangest / memorable job in research?
Beginning work at 7am daily in the endoscopy unit at Royal Prince Alfred Hospital, prior to attending medical degree lectures, to ask patients to let me take their blood tests for research into endoscopy risks.
What is the craziest thing you have ever had to do “in the name of research”?
Writing a PhD thesis is a major commitment and would be considered ‘crazy’ by some!
What do you do to relax?
Mountain biking, but anything outdoor will suffice!